Clinical Trials Logo

Muscle Loss clinical trials

View clinical trials related to Muscle Loss.

Filter by:

NCT ID: NCT05804604 Completed - Bone Loss Clinical Trials

Bone Intake Proteins and Muscle Mass Deficiency in Proximal Femur Fractures

Start date: May 7, 2022
Phase:
Study type: Observational

The aim of this clinical trial is to compare serum concentration of bone intake proteins [ sex hormone-binding globulin (SHBG), cross linked C-telopeptide of type I collagen (CTX-I)] and muscle atrophy marker [creatine kinase (CK-MB)] between patients after the fracture of proximal femur and their age corresponding counterpart without the fracture. The main question it aims to answer is: • Is the higher concentration of bone intake proteins and muscle atrophy marker a predictive factor of proximal femur fracture? The part of participants (Group 1) will be hospitalized at the Department of Orthopaedics and Rehabilitation and will undergo a surgical treatment (open reduction of the fracture). The rest (Group 2) will be admitted to the Department of Internal Medicine. Participants of both Groups will have the blood sample test taken, to evaluate and compare the serum concentration of SHBG, CTX-I and CK-MB proteins.

NCT ID: NCT05795556 Recruiting - Sarcopenia Clinical Trials

Biomarkers of Sarcopenia and Frailty in Geriatric Patients

BioFrail
Start date: November 8, 2021
Phase:
Study type: Observational

During the last decades there has been an increase in the relative proportion and life expectancy of elderly people. Hence, the number of elderly with diseases and disabilities related to aging will increase and consequently, age-related losses in skeletal muscle mass and physical function represents an important current and future public health issue. Sarcopenia is a progressive and generalized skeletal muscle disorder that is considered central to the development of physical deconditioning and untreated sarcopenia is linked to falls, morbidity, and mortality. The underlying mechanisms behind the progressive loss of muscle mass and function associated with aging are yet unknown but seems to be multifactorial. A decrease in physical activity level and an altered central and peripheral nervous system innervation have been identified as some of the contributing factors. Furthermore, chronic low-grade inflammation has been proposed as a central contributor to sarcopenia and thus physical frailty. However, it is not yet clear whether the elevated markers of inflammation seen in the elderly are due to aging, chronic illness, or inactivity. But overall, it seems that inflammation plays an important role in the development of muscle loss, and is related to increased risk of falls, fragility, and early death.

NCT ID: NCT05776862 Recruiting - Insulin Resistance Clinical Trials

Study Testing Benefits of Ursolic Acid (UA) as a Countermeasure To Myopenia and Insulin Resistance in Chronic Spinal Cord Injury (SCI)

Start date: March 27, 2023
Phase: Phase 2
Study type: Interventional

This study will evaluate if Ursolic Acid supplementation may be effective in reducing muscle loss and improving blood sugar control in the SCI community.

NCT ID: NCT05647135 Not yet recruiting - Trauma Clinical Trials

ImpACt of Very High Protein Content Enteral nUtrition Formulas on Critically Ill MUltipLe trAuma paTiEnts

ACCUMULATE
Start date: December 1, 2022
Phase:
Study type: Observational [Patient Registry]

This prospective observational randomized study aims to determine energy, protein intake and gastrointestinal tolerance while using enteral nutrition formulas with very high protein content and enteral nutrition formulas with normal protein content. - Differences regarding achieving protein and calorie daily targets when using enteral nutrition formulas with different protein content - Differences regarding residual gastric volume when using enteral nutrition formulas with different protein content - Differences regarding body composition when using enteral nutrition formulas with different protein content

NCT ID: NCT05570474 Recruiting - Clinical trials for Bariatric Surgery Candidate

Effect of Protein Supplementation on Fat Free Mass Preservation After Bariatric Surgery

PROMISE
Start date: September 1, 2022
Phase: N/A
Study type: Interventional

This double blind randomized placebo controlled trial investigates the effect of protein supplementation on fat free mass loss in patients who underwent a Roux-en-Y gastric bypass.

NCT ID: NCT05531305 Completed - Critical Illness Clinical Trials

Longitudinal Changes in Muscle Mass After Intensive Care

Start date: September 26, 2022
Phase: N/A
Study type: Interventional

Critically ill patients often suffer from dramatic muscle loss while in the ICU. Recovery of muscle structure and function have been proposed as core outcome measures for interventional studies in ICU survivors. Ultrasound is an accessible and validated tool to monitor muscle mass over time, with quadriceps muscle layer thickness (MLT) corresponding well to more invasive or cumbersome modalities. In order to design adequately powered studies investigating the effects of nutritional or metabolic interventions on post-ICU recovery, an estimate of the population standard deviation in MLT change over time is required. Currently there is a paucity of data describing changes in muscle mass during the subsequent period of hospitalization in ICU survivors. The aim of this study is to estimate the mean change and standard deviation in quadriceps MLT over time, in patients discharged alive from intensive care. Patients will be followed until hospital discharge or up to 28 days after ICU discharge. Interactions with nutritional intake, inflammation and metabolic rate will be analyzed for hypothesis-generating purposes.

NCT ID: NCT05497960 Completed - PreDiabetes Clinical Trials

Vivo Prediabetes Study: Online, Live, and Interactive Strength Training for Older Adults With Prediabetes

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

This research trial studies the effect of an online, live and interactive strength training program on physical function and strength in older adults with prediabetes.

NCT ID: NCT05482243 Recruiting - Kidney Diseases Clinical Trials

Protein and Exercise Training in Chronic KIDNEY Disease

PET KIDNEY
Start date: January 1, 2023
Phase: N/A
Study type: Interventional

When patients progress to the final stage of chronic kidney disease (CKD) and require hemodialysis treatment, they typically have lost so much muscle function that they are no longer physically independent. However, due to disease- and hemodialysis-related muscle catabolism, dietary protein and exercise interventions are only capable to attenuate the decline in physical function of patients on hemodialysis treatment. Therefore, lifestyle interventions to increase muscle function should be implemented before hemodialysis is required. However, it is still a matter of debate whether muscle protein synthesis rates of patients with advanced CKD can be increased with a patient-tailored dietary protein and exercise intervention.Therefore, the current study will assess MPS rates during habitual lifestyle and during an interventional program including dietary protein and exercise in patients with advanced CKD. In addition, we will compare MPS rates during free-living conditions between patients with advanced CKD and healthy controls.

NCT ID: NCT05296096 Recruiting - Pediatric ALL Clinical Trials

PRotein Optimization With eXercise to Improve MUscle Mass and Functional outcomeS

PROXIMUS
Start date: February 20, 2023
Phase: N/A
Study type: Interventional

The investigators have designed a 2-center, pilot feasibility, randomized controlled trial (PROXIMUS) to determine the feasibility and safety of a larger multi center, randomized open-label trial comparing high protein combined with individualized exercise vs. standard management during the acute phase of critical illness in children. The investigators aim to determine the impact of the intervention on preservation of muscle mass; and functional status at 1 month and 6 months after randomization.

NCT ID: NCT05284149 Recruiting - Sarcopenia Clinical Trials

Study the Impact of Hirsutella Sinensis Nutrient Supplements Has on Improving Muscle Health and Metabolism in Elderly

HSN
Start date: February 15, 2022
Phase: N/A
Study type: Interventional

Sarcopenia has now been officially recognized as a muscle disease related to aging, which may increase the risk of falls and fractures and both heart and respiratory diseases in the elderly. Sarcopenia causes inconvenience in the elderly, affecting their quality of life and often requiring long-term care or even resulting in death. Moreover, the elderly often encountered malnutrition due to inadequate nutrient intake and scarce nutrient diversity. Furthermore, malnutrition is often one of the leading causes of sarcopenia. Therefore, effective nutritional supplementation is essential to improve or prevent muscle loss for the elderly. Cordyceps sinensis is a well-known valuable traditional Chinese medicine and Hirsutella sinensis was an asexual strain of Cordyceps sinensis. Researchers have found that Hirsutella sinensis can help to increase connection between gastrocnemius muscle fibers and spinal nerve under the amyotrophic lateral sclerosis animal disease model. However, culturing conditions for Hirsutella sinensis are extremely difficult and long, one of the key culturing condition is the temperature, must be maintaining at 16-20℃for 45 days. Fortunately, Grape King Biotech has core technology using liquid fermentation which greatly shortened the cultivation time, thus, providing sufficient and safe products to patients. The investigators designed a randomized placebo-controlled study first to investigate the relationship and clinical impact Hirsutella Sinensis had on muscle mass and function in the elderly. Second, investigate the metabolic impact Hirsutella Sinensis had on muscle mass.